Edition:
United States

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

20.92USD
2:13pm EDT
Change (% chg)

$0.23 (+1.11%)
Prev Close
$20.69
Open
$20.62
Day's High
$21.00
Day's Low
$20.62
Volume
37,114
Avg. Vol
255,449
52-wk High
$27.07
52-wk Low
$7.20

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.57
Market Cap(Mil.): $981.69
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

Aug 15 2017

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

Aug 08 2017

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

Aug 04 2017

BRIEF-Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy

* FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy

Jun 13 2017

BRIEF-Omeros completes IGA nephropathy cohort in OMS721 phase 2 clinical trial

* Omeros announces completion of IGA nephropathy cohort in OMS721 phase 2 clinical trial

May 17 2017

BRIEF-Omeros reports Q1 revenue $12.3 million

* Omeros Corporation reports first quarter 2017 financial results

May 10 2017

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

Mar 30 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.37 -2.85
Novartis AG (NOVN.S) CHF82.90 +0.15
Pfizer Inc. (PFE.N) $35.82 +0.37
Roche Holding Ltd. (ROG.S) CHF247.00 +2.20
Roche Holding Ltd. (RO.S) CHF247.60 +1.90
Merck & Co., Inc. (MRK.N) $65.23 -0.72
Bayer AG (BAYGn.DE) €109.85 -0.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.30 +0.05
Eli Lilly and Co (LLY.N) $81.44 -0.29

Earnings vs. Estimates